Tardive Dyskinesia Therapeutics Market Size

Tardive Dyskinesia Therapeutics Market Size

Tardive Dyskinesia Therapeutics Market size was valued at USD 3.1 billion in 2023 growing at a CAGR of 7.1% between 2024 and 2032, driven by factors such as the increase in the prevalence of tardive dyskinesia (TD).

For instance, as per the report published by Mental Health America, it has been reported that, tardive dyskinesia is estimated to affect at least 600,000 people in the U.S. alone. Anyone who has been treated for schizophrenia, schizoaffective disorder, bipolar disorder, anxiety, and/or depression and has taken or is taking psychotropic drugs is at risk for developing TD. Also, the risk for developing TD increases if the patients are 55 years of age or older, postmenopausal, have a history of substance abuse, or have a mood disorder. Thus, the rise in the prevalence of neurological disorders along with increase in consumption of antipsychotic drugs will spur the market growth.
 

Tardive dyskinesia (TD) is an involuntary neurological movement disorder caused using dopamine receptor blocking drugs that are prescribed to treat certain psychiatric or gastrointestinal conditions. Long-term use of antipsychotic drugs and gastrointestinal therapeutics may produce biochemical abnormalities in the brain known as the striatum. The movement disorders include akathisia, dystonia, buccolingual stereotypy, myoclonus, chorea, tics, and other abnormal involuntary movements, which are commonly caused by the long-term use of typical antipsychotics.